A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248.

Trial Profile

A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Oct 2012 Final results presented at the 37th Congress of the European Society for Medical Oncology.
    • 02 Oct 2012 Status changed from active, no longer recruiting to completed, based on the abstract presented at ESMO.
    • 25 Aug 2012 Planned number of patients changed from 4574 to 5000 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top